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Abstract 
Background. The use of autologous or allogenic stem cells has recently been suggested as an alternative 
therapeutic approach for treatment of cartilage defects. Bone marrow mesenchymal stem cells (BM-
MSCs) are well-characterized multipotent cells that can differentiate into different cell types. 
Understanding the potential of these cells and the molecular mechanisms underlying their differentiation 
should lead to innovative protocols for clinical applications. The aim of this study was to evaluate the 
usefulness of surface antigen selection of BM-MSCs and to understand the mechanisms underlying their 
differentiation. 
Methods. MSCs were isolated from BM stroma and expanded. CD105+ subpopulation was isolated using 
a magnetic separator. We compared culture-expanded selected cells with non-selected cells. We analyzed 
the phenotypic profiles, the expression of the stem cell marker genes Nanog, Oct3/4, and Sox2 and the 
multi-lineage differentiation potential (adipogenic, osteogenic, and chondrogenic). The multi-lineage 
differentiation was confirmed using histochemistry, immunohistochemistry and/or real-time polymerase 
chain reaction (qPCR) techniques. 
Results. The selected and non-selected cells displayed similar phenotypes and multi-lineage 
differentiation potentials. Analyzing each cell source individually, we could divide the six donors into 
two groups: one with a high percentage of CD29 (β1-integrin) expression (HL); one with a low 
percentage of CD29 (LL). These two groups had different chondrogenic capacities and different 
expression levels of the stem cell marker genes. 
Conclusions. This study showed that phenotypic profiles of donors were related to the chondrogenic 
potential of human BM-MSCs. The chondrogenic potential of donors was related to CD29 expression 
levels. The high expression of CD29 antigen seemed necessary for chondrogenic differentiation. Further 
investigation into the mechanisms responsible for these differences in BM-MSCs chondrogenesis is 
therefore warranted. Understanding the mechanisms for these differences will contribute to improved 
clinical use of autologous human BM-MSCs for articular cartilage repair. 
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1. Introduction 
Damaged or degenerated articular cartilage has limited capacity for regeneration. Because of the lack of 
vascularity, the normal mechanisms of tissue repair, involving humoral factors and recruitment of 
stem/progenitor cells to the damage site, do not occur (Steinert et al., 2007 and Hardingham et al., 2002). 
Successful treatment of cartilage lesions remains an intractable problem. Tissue engineering is a new 
clinical approach for repair of tissue damage and has the potential to provide cartilaginous constructs 
capable of restoring the normal function of articular cartilage (Buckwalter and Mankin, 1998). The recent 
use of autologous or allogenic stem cells has been suggested as an alternative therapeutic approach for 
treatment of cartilage defects (Jung et al., 2009). 
Mesenchymal stem cells (MSCs), one type of adult stem cells, are undifferentiated, non-hematopoietic 
cells that undergo multiple and sequential cell divisions. They have the capability to self-renew and are 
responsible for repair and repopulation of damaged tissues in the adult (Hombach-Klonisch et al., 2008). 
For these reasons MSCs are a promising cell resource for tissue engineering and cell-based therapies 
(Pittenger, 2008). 
MSCs are currently defined by the combination of four minimal criteria proposed by the International 
Society for Cellular Therapy in 2006 (Dominici et al., 2006): adherence to plastic in standard culture 
conditions; absence of the hematopoietic markers, CD34 and CD45, and presence of CD105 (endoglin, 
SH2), CD73 (ecto-5′ nucleotidase, SH-3, SH-4), and CD90 (Thy-1) surface antigens; capability of multi-
lineage differentiation, confirmed by staining of in vitro cultures. 
Bone marrow represents the most commonly used tissue source for the isolation of MSCs (Pittenger et 
al., 1999). Bone marrow MSCs (BM-MSCs) are well-characterized multipotent cells, which can 
differentiate into different cell types (osteocytes, adipocytes, tenocytes, and chondrocytes) (Bianco et al., 
2001). 
MSCs present in isolated BM cells are approximately 1 cell per 5×103 mononuclear cells (Kastrinaki 
et al., 2008). Therefore, it is necessary to expand BM-MSCs in vitro to obtain adequate cell numbers for 
clinical purposes. This expansion has the potential to induce alteration of stem cell characteristics, 
senescence or spontaneous transformation ( Rubio et al., 2005). 
To resolve this problem, the enrichment of MSCs and their stem cell properties through surface 
antigens used for positive or negative selection of cells has been proposed (Tondreau et al., 2004, Aslan et 
al., 2006, Kastrinaki et al., 2008 and Jarocha et al., 2008). The identification of the more immature 
fraction is based on the expression level of stem cell marker genes: Nanog (Mitsui et al., 2003), Oct3/4 
(Nichols et al., 1998), and Sox2 (Avilion et al., 2003). All of these are transcriptional factors controlling 
the expression of a variety of genes related to the regulation of pluripotency and the self-renewal potential 
of stem cells (SCs). The down-regulation of these three transcription factors has been associated with the 
induction of cell differentiation. 
The use of the more immature cell fraction could allow the expansion of BM-MSCs in culture without 
affecting their multi-potentiality and differentiation capacity. This could be useful for cell therapy where 
clinical applications require differentiated cells, in particular for cartilage tissue engineering, where the 
use of differentiated chondrogenic progenitors has to be preferred on the use of undifferentiated stem 
cells. 
The process by which MSCs differentiate towards chondrocytes is called chondrogenesis (Goldring et 
al., 2006). There are a number of different protocols for inducing in vitro differentiation of BM-MSCs 
toward mature chondrocytes. To mimic mesenchymal condensation and cell–cell interactions, MSCs are 
cultured in high density aggregates (pellet culture) ( Johnstone et al., 1998 and DeLise et al., 2000). To 
induce chondrogenic differentiation, MSCs are cultured in a specific medium containing dexamethasone ( 
Derfoul et al., 2006) and transforming growth factor β (TGFβ) ( Spagnoli et al., 2007), one of the earliest 
signals in chondrogenic condensation ( Tuli et al., 2003). The differentiation protocols currently used lead 
to the expression of chondrocyte hypertrophy-associated genes ( Sekiya et al., 2002 and Pelttari et al., 
2006). Because of this, it is imperative to develop well-defined and efficient methods for directing in vitro 
stem cell differentiation into the chondrogenic lineage. 
In recent years, many studies have focused on developing better culture conditions or better 
subpopulations of MSCs able to differentiate towards mature chondrocytes (Heng et al., 2004). Some 
studies have analyzed the use of antigen surface marker selection of MSCs. The starting point of these 
experiments was the enrichment of stem cell specific marker genes. However, this enrichment has not 
always led to better differentiation capacity of the selected cell populations. These studies have found 
little or no improvement in the differentiation capacity towards adipocytes, osteocytes, and chondrocytes 
(Kastrinaki et al., 2008) or the capability of the selected cells to differentiate towards these three lineages 
(Aslan et al., 2006 and Arufe et al., 2009), or a better osteogenic potential of the populations analyzed 
(Jarocha et al., 2008). 
The aim of this study was to evaluate the usefulness of surface antigen selection of different MSC 
populations and to elucidate the mechanisms underlying their differentiation. For this purpose, we 
characterized and compared two cell populations, selected (CD105+) and non-selected BM-MSCs (total-
BM). We selected the surface antigen CD105 due to its wide expression in MSCs (Barry et al., 1999). We 
analyzed the multi-lineage differentiation potential of these two populations (adipocytes, osteocytes, and 
chondrocytes) with a focus on their chondrogenic differentiation capacity in both normoxic and hypoxic 
conditions.  
2. Materials and methods 
2.1. Isolation and culture of MSCs 
The bone marrow samples used to isolate mesenchymal stem cells (BM-MSCs) were obtained from six 
patients (mean age: 56 years; range: 40–72 years) undergoing total hip replacement due to osteoarthritis. 
The donors were not selected; the first six samples submitted were processed as they arrived at the 
laboratory unit. This study was approved by the institutional review board, and informed consent was 
obtained from all subjects in the study. 
Isolated bone marrow cells were cultured in monolayer in Dulbecco’s modified Eagles medium 
(DMEM), 20% fetal bovine serum (FBS), 1% penicillin and streptomycin (P/S) (all from Sigma-Aldrich, 
St. Louis, MO, USA) until 90% confluent. Pre-plating for 15 min in the first two passages eliminated any 
fibroblasts remaining in the culture (Richler and Yaffe, 1970). 
When the cells were 90% confluent, the CD105+ subpopulation was isolated by magnetic separation 
(MACS separator, Miltenyi Biotec, Madrid, SP) following the manufacturer’s instructions. Briefly, a 
portion of the adherent cells at the fourth culture passage was trypsinized, washed, resuspended in MACS 
buffer and incubated with anti-CD105 antibodies conjugated to magnetic microbeads. After incubation, 
the cells were passed through a magnetic column. The cells retained (CD105+) and the cells not passed 
through the column (total-BM) were cultured and expanded until the beginning of the differentiation 
experiments. 
2.2. Phenotypic characterization using flow cytometry 
After culture expansion for a total of 7–9 passages, the cells were trypsinized, washed and analyzed by 
flow cytometry. Briefly, the human BM-derived cells were harvested by trypsinization, washed and 
centrifuged at 300g for 8 min. The cells were counted prior to flow cytometry and a total of 2×105 were 
transferred to fluorescence-activated cell sorting (FACS) polypropylene tubes. The antibodies listed in 
Table 1 were used for these experiments. Optimal amounts of monoclonal antibodies (mAbs) were 
determined and added to each tube for 40 min at 4 °C in darkness. Most antibodies were conjugated with 
fluorescein isothiocyanate (FITC) or phycoerithrin (PE) and were specific for markers associated with 
mesenchymal and hematopoietic lineages. When necessary, cells were incubated for 30 min at 4 °C in 
darkness with a secondary FITC-conjugated antibody to allow binding to the primary antibody. A control 
tube for each of the chromogens used contained equivalent amounts of isotype standards. A minimum of 
25,000 cell events per assay were acquired on a FACsCalibur flow cytometer (BD Biosciences, Madrid, 
Spain). Data were analyzed using Cell Quest software (BD Biosciences) and the results were expressed as 
percent positive. 
Table 1. Antibodies used in flow cytometry for phenotypic characterizations. 
Antibody Specificity Source 
   
R-PE-CD29 β1 Integrin BD Pharmingen 
R-PE-CD34 Hemopoietic progenitor cell antigen 1 (HPCA1) BD Pharmingen 
FITC-CD44 Homing cellular adhesion molecule (HCAM) BD Pharmingen 
FITC-CD45 Leukocyte common antigen (LCA) BD Pharmingen 
PE-CD73 Ecto-5′-nucleotidase BD Pharmingen 
PE-Cy5-CD90 Thy-1 BD Pharmingen 
FITC-CD105 Endoglin, SH2 Chemicon 
CD117 c-kit, stem cell factor receptor (SCFR) BD Pharmingen 
R-PE-CD166 Activated leukocyte cell adhesion molecule (ALCAM) BD Pharmingen 
SSEA-4 Stage-specific embryonic antigen 4 (SSEA-4) R&DSystems 
STRO-1 Stromal antigen 1 (STRO-1) Developmental Studies Hybridoma Bank 
   
  
2.3. Multipotential characterization 
At the time of phenotypic analysis, after 7–9 culture passages for expansion, the cells were differentiated 
towards adipocyte, osteocyte, and chondrocyte lineages. 
2.4. Adipogenic differentiation 
The 7–9 passage BM-MSCs were detached using trypsin-EDTA, seeded at 1.5×105 cells/cm2 in a 
chamber slide and cultured in growth medium until confluent. Adipogenesis was induced by culturing for 
three weeks in Bullekit Adipogenic Differentiation Medium (Lonza, Barcelona, Spain), following the 
manufacturer’s instructions. Each differentiation point was compared to a control point corresponding to 
cells cultured for the same period of time in DMEM with 20% FBS. Differentiation was confirmed by 
detection of cytoplasmic lipid droplets by oil red O staining after cell fixation in 4% paraformaldehyde. 
2.5. Osteogenic differentiation 
BM-MSCs at the 7th–9th passages were detached using trypsin-EDTA, seeded at 1.5×105 cells/cm2 in a 
chamber slide and cultured in growth medium until confluent. Osteogenesis was induced by culture for 
three weeks in hMSC Bullekit Osteogenic Differentiation Medium (Lonza). This culture medium was 
changed every 2–3 days. Each differentiation point was compared with a control point that corresponded 
to cells cultured for the same period of time with DMEM and 20% FBS. Differentiation was confirmed 
by alizarin red staining after cell fixation in 4% paraformaldehyde to assess the presence of calcium 
deposits. 
2.6. Chondrogenic differentiation 
Chondrogenesis was assessed using the micropellet formation (2.5×105 cells) technique (Johnstone et al., 
1998), with some modifications. BM-derived cells from the 7th to 9th passages were detached using 
trypsin-EDTA and centrifuged at 300g for 10 min. The resulting pellet was cultured in chondrogenic 
differentiation medium ( Livak and Schmittgen, 2001) both in normoxic humidified atmosphere with 5% 
CO2 and hypoxic conditions obtained using the GasPak™ EZ Anaerobe Pouch System (BD Diagnostics). 
The medium used for the first two days contained DMEM with 15% fetal calf serum (FCS), 
supplemented with 5 mg/ml ascorbic acid (AA), 1/1000 monotioglycerol (MTG), and 1% P/S to promote 
chondrogenic induction. This medium was replaced by DMEM with 15% knockout serum (Gibco, 
Madrid, Spain), 1% P/S and supplemented with 5 mg/ml AA, 10 μM dexamethasone, 6 μg/ml transferrin, 
1×10−7 M retinoic acid, and 1 ng/ml of recombinant human transforming growth factor-β3 (TGF-β3) 
(Prospec-Tany Technogene Ltd., Rehovot, Israel) for 2, 4, 7, 14, 21, and 28 days. The culture medium 
was changed every 2–3 days. Each time point of the differentiation assay was compared with cells 
cultured for the same period of time with DMEM and 20% FBS. Differentiation was assessed through 
histological, immunohistochemical, and qPCR techniques. Cell aggregates were embedded in Tissue-
Tech OCT compound (Sakura Finetek) and frozen. The presence of hyaline cartilage-characteristic 
molecules, such as collagen type II and proteoglycans, was detected by histological, 
immunohistochemical, and qPCR techniques as described below. 
2.7. Histological analyses 
For chondrogenesis evaluation, 4 μm-thick frozen sections of aggregates were stained with hematoxylin 
and eosin (HE), Masson’s trichrome (MT), toluidine blue (TB), and safranin O (SaO) for proteoglycans 
and collagens. 
2.8. Immunohistochemical analyses 
For chondrogenesis evaluation, 4 μm-thick frozen sections were incubated with primary antibodies (Table 
2) to detect the presence of collagen types I (Abcam, Cambridge, UK) and II (Neomarker, Barcelona, 
Spain), and with a polyclonal antibody to detect aggrecan C-20 (Santa Cruz Biotechnology, Heidelberg, 
Germany). The peroxidase/DAB ChemMateTM DAKO EnVision™ detection kit (Dako, Barcelona, 
Spain) was used to determine antigen–antibody interactions. Negative staining controls were achieved by 
omitting the primary monoclonal antibody. Samples were visualized using an optical microscope. 
Table 2. Antibodies used for immunohistochemical analyses. 
Specificity Clone Source 
   
Collagen type I COL1 Abcam 
Collagen type II 6B3 Neomarker 
Aggrecan C-20 Polyclonal Santa Cruz Biotechnology 
   
 
2.9. RNA extraction 
Isolation of total RNA from cell cultures was accomplished using Trizol Reagent (Invitrogen, Barcelona, 
Spain), following the manufacturer’s protocol. RNA was assessed for quantity at 260 nm using a 
NanoDrop™ spectrophotometer (Thermo Scientific, Madrid, Spain). The A260/A280 ratio was calculated 
to assess quality and purity. Total RNA (1 μg) was further processed in RT-PCR or stored at −80 °C until 
use. 
2.10. cDNA synthesis 
Before reverse-transcription, the total RNA underwent DNase digestion (Fermentas) for complete 
removal of DNA contamination. Subsequently, the reverse-transcription reaction was performed from 
1 μg of total RNA following the manufacturer’s instructions, using SuperScript™ First-Strand Synthesis 
System for RT-PCR (Invitrogen™, Spain) to a total volume of 20 μl in a Thermocycler (Gene Amp PCR 
System 9700, Applied Biosystem, Madrid, Spain). 1 μg of total RNA, 0.5 μg oligo d(T), 0.5 mM of dNTP 
mix, and 3 μl of DEPC-treated water were denatured at 65 °C for 5 min and chilled on ice for at least 
1 min. Then, 2 μl of 10×RT buffer, 5 mM MgCl2, 0.01 M DTT, and 40 U of RNaseOUT Recombinant 
Ribonuclease Inhibitor were mixed, collected by centrifugation and incubated at 42 °C for 2 min. After 
incubation, 50 U of SuperScript™ RT were added and incubated at 42 °C for 50 min and 70 °C for 
15 min in a Thermocycler (Gene Amp PCR System 9700, Applied Biosystems). Finally, samples were 
chilled on ice and incubated with 2 U of RNAse H for 20 min at 37°C before proceeding to the next step. 
Samples were stored at −20 °C before the amplification of target cDNAs. Positive and negative 
controls were included in each experiment. RNA extraction, reverse-transcription-PCR assay setup and 
post-reverse-transcription-PCR product analysis were carried out in separate dedicated rooms to prevent 
cross-contamination. 
2.11. Quantitative real-time reverse-transcription-PCR analysis (qRT-PCR) 
Real-time PCR analysis was performed, using the primers shown in Table 3, on LightCycler® 480 
Instrument (Roche, Mannheim, Germany).  
Table 3. Sequences of the quantitative polymerase chain reaction (qPCR) primers used for amplification of the human mRNA 
corresponding to chondrogenic-specific genes and stem cell marker genes. 
    
Gene name Forward primer (5′–3′) Reverse primer (5′–3′) mRNA ID number 
Sox2 ctccgggacatgatcagc ggtagtgctgggacatgtgaa NM_003106 
Oct3/4 ggtggagagcaactccaatg tctgcagagctttgatgtcc DQ486513 
Nanog atgcctcacacggagactgt aagtgggttgtttgcctttg NM_024865 
Cadherin 2 (Cdh2) agtatccggtccgatctgc ctgtggggtcattgtcagc NM_001792 
Tenascin-C (Tnc) ggtacagtgggacagcaggt cccctttgtaggacagagca NM_002160 
Sox9 gtacccgcacttgcacaac tcgctctcgttcagaagtctc NM_000346 
Collagen type 2A1 (Col2A1) gtgtcagggccaggatgt tcccagtgtcacagacacagat NM_001844 
Aggrecan (Agg) gcctacgaagcaggctatga gcacgccataggtcctga BC036445 
Runx2 gtgcctaggcgcatttca tgactggcggggtgtaag NM_001024630 
Collagen type X (Col10) caccttctgcactgctcatc ggcagcatattctcagatgga NM_000493 
Matrix metalloprotease 13 
(MMP13) 
ccagtctccgaggagaaaca aaaaacagctccgcatcaac NM_002427 
Collagen type I (Col1) gtgatgctggtcctgttggt caccatcgtgagccttctct NM_000088 
β-Actin agagctacgagctgcctgac ggatgccacaggactcca NM_001101 
    
 
The PCR reaction consisted of 10 μl of Master Mix 2×concentrate, 0.25 μM of each forward and 
reverse primer, the cDNA template and PCR-grade water up to a final volume of 20 μl in the LightCycler 
480 Multiwell Plate 96. The multiwell plate was loaded in the LightCycler 480 Instrument until the PCR 
program started. 
The initial enzyme activation at 95 °C for 10 min was followed by 50 cycles of target amplification 
consisting of three sequential steps: 95 °C for 10 seconds (s), 61 °C for 5 s, and 72 °C for 7 s. After 
amplification, a melting curve analysis was performed and a final cooling step was applied at 40 °C for 
20 s. 
The single amplification and expected size of each PCR product were verified. The use of 2% agarose 
gel electrophoresis, stained with SYBR®Safe DNA gel stain (Invitrogen™), of all PCR products revealed a 
single band that corresponded to the single-amplified products as predicted by the PCR melting curve 
analysis. 
PCR primers were positioned to span exon–intron boundaries, reducing the risk of detecting genomic 
DNA. The primers were purchased from Roche (Mannheim, Germany). The β-Actin gene (β-Act) was 
used as the internal control housekeeping gene to normalize the amount of target cDNA. 
Data analysis was performed using LightCycler 480 Relative Quantification software (Roche). 
Relative levels of expression were calculated by the 2−ΔΔCt method (Livak and Schmittgen, 2001). Each 
assay was done at least in triplicate and included marker-positive and marker-negative controls and 
reagent with no template controls. Each data was normalized against the housekeeping gene and 
compared with its corresponding control point of cells grown in DMEM with 20% FBS. For each gene 
expression, we assigned the value 1 to the lowest level of expression and the other values were measured 
as relative expression levels (R.E.L). 
2.12. DNA sequencing analysis 
At least one PCR product coming from each real-time PCR experiment was used as template DNA. PCR 
products were purified by an enzymatic method (ExoSAP-IT, Amersham Biosciences). DNA sequencing 
was performed in a reference facility on ABI 3100 (Applied Biosystems) using Big Dye terminators. 
Forward and reverse specific primers used were the same as for the qPCR experiments (Table 3). 
2.13. Other procedures 
Standard procedures for manipulation of nucleic acids were essentially those followed in Sambrook et al. 
(1989).  
2.14. Statistical analysis 
Each experiment was repeated at least three times. The statistical significance of the differences between 
mean values was determined using a two-tailed t test; p<0.05 was considered significant. Results are 
expressed as the mean±standard deviation (mean±SD). 
3. Results 
3.1. Isolation of BM-MSCs populations 
Spindle-shaped bipolar cells attached to the flask were observed at the first medium change at 48 h of 
culture. We magnetically selected, differentiated, and analyzed the characteristics and multi-potentiality 
of two subsets of cells: unselected (not passed through the magnetic column, total-BM) and CD105-
selected cells (retained by magnetic column, CD105+), obtained as described in Section 2. 
4. Characterization of the BM-MSC populations 
4.1. Phenotypic analysis 
For BM-MSCs at the fourth passage, the percent of CD105-positive cells was between 73% and 86% 
before separation and increased to 95% in the CD105+ fraction, after the separation step. 
At the beginning of the differentiation experiments after culture expansion, the two subsets of cells 
were characterized phenotypically using flow cytometry. These cell subsets both showed very similar 
expression of surface markers without any statistically significant differences. The total-BM-MSCs and 
the CD105+ subset showed CD73 and CD44 antigens co-expressed at 88% and 95%, respectively; 
CD105 was expressed at 78% and 82%, respectively; and CD166 was expressed at 82% and 84%, 
respectively (Fig. 1). The percentage of CD90 expression was around 94% and of CD29 was around 90% 
(Fig. 1) in both subsets. The expression levels for CD271 and SSEA-4 ranged from 15% to 30%, and 
CD117 and Stro-1 were not seen in our populations. CD45 and CD34 were also absent (data not shown). 
 
 
 
Fig. 1. Surface antigen expressions of non-selected (total-BM) and selected (CD105+) cells. Each value is given as the percent of 
positive cells. 
4.2. Multi-differentiation potential 
We induced adipogenic, osteogenic, and chondrogenic differentiation to confirm the multi-potentiality of 
our cultured expanded cells (Fig. 2).  
 
 
 
Fig. 2. Staining techniques for non-selected (total-BM) and selected (CD105+) differentiated cells. The photos are from day 21 of 
culture. (a) Oil Red O staining of cells differentiated toward adipocytes, compared to the control cells cultured for the same times in 
Dulbecco’s Modified Eagles Medium (DMEM) with 20% fetal bovine serum (FBS). (b) Alizarin Red staining of cells differentiated 
toward osteoblasts compared to the control cells cultured for the same duration in DMEM with 20% FBS. (c) Histochemical 
HE=hematoxylin–eosin; MT=Masson’s thrichome; TB=toluidine blue; SaO=safranin O staining results and immunohistochemical 
results for collagen type II (Col2A1) cells differentiated toward chondrocytes. 
After 21 days of culture with the appropriate differentiation medium or with 20% FBS for the 
controls, the cells were stained with Oil Red O for lipid droplets to evaluate adipogenic differentiation 
(Fig. 2a), or with Alizarin Red for calcium deposits to evaluate osteogenic differentiation (Fig. 2b). All 
the controls were negative for staining, showing the absence of lipid droplets or calcium deposits, while 
the cells grown in differentiation media were positively stained, showing the presence of lipid droplets or 
calcium deposits, indicating differentiation. The total-BM fraction showed a trend to have a higher 
differentiation potential, however, without statistically significant differences. 
To evaluate chondrogenic potential at 2, 4, 7, 14, 21, and 28 days of culture, either with differentiation 
medium or with 20% FBS, the aggregates were analyzed by histochemistry using hematoxylin–eosin 
(HE), Masson’s thrichrome (MT), toluidine blue (TB) and safranin O (SaO) staining, and 
immunohistochemistry for aggrecan and collagen types I and II. These techniques confirmed 
chondrogenic differentiation with no appreciable differences between the selected and unselected cells. 
Histochemistry showed no differences among days 2, 4, and 7 of culture (data not shown). Chondrogenic 
differentiation was detectable between days 14 and 21 of culture with no appreciable differences between 
normoxic and hypoxic conditions. At these analysis times, the presence of collagens and proteoglycans 
could be seen with no appreciable differences between the populations studied (Fig. 2c; photos show 
results at day 21 of culture and are representative of both times of analysis). Immunohistochemistry 
results for aggrecan (Agg) and Col1 were negative for all the times studies (data not shown). 
4.3. Quantification of stem cell markers 
To determine whether the selected cells represent a more immature phenotype, we analyzed and 
compared the presence of stem cell marker genes (Sox2, Nanog, and Oct3/4) at the beginning of each 
experiment.  
For each gene, the reference value 1 was given to the lowest expression level and the results were 
measured as relative expression levels (R.E.L). Using this quantification, CD105+ cells appeared to be 
the more immature fraction, which showed a higher expression of Sox2, Nanog, and Oct3/4 (3.03, 1.49, 
and 3.40 times, respectively). However, these differences are not statistically significant (Fig. 3). 
 
 
 
Fig. 3. Stem cell marker gene expression levels of non-selected (total-BM) and selected (CD105+) cells at the start of experiments. 
For each gene the reference value 1 is assigned to the lowest expression level. 
5. Characterization of cell sources: donor influence on chondrogenesis 
Analyzing each cell source individually, we could divide the six donors into two groups: A, B, and C 
represent the first group; D, E, and F the second one. This division was based on differences in the 
expression of the CD29 surface marker among the donors. 
Table 4 shows the data for age, sex, and surface marker expressions of the donors. Differences in the 
expression of CD73/CD44 and CD105 were not statistically significant, but the differences in CD29 
expression were significant (p<0.005). The first group, designated the low level (LL) group, had a CD29 
expression lower than 90%, while in the second group, designated the higher level (HL), the CD29 level 
exceeded 90%. No differences other than CD29 level was found between these groups.  
Table 4. Characteristics of the donors included in the study. The division into two groups was based on CD29 surface antigen 
expression. 
DONOR A B C 
 
D E F 
        
YEARS 61 40 72  65 60 40 
SEX Female Male Female  Female Male Male 
CD73/CD44 85 75 94  99 80 98 
CD105 73 60 82  87 75 82 
CD166 84 77 76  93 80 96 
CD29 87 76 82  93 96 94 
CD271 15 Neg 25  Neg 22 30 
CD117 Neg Neg Neg  Neg Neg Neg 
SSSEA4 Neg 15 30  18 Neg 26 
Stro-1 Neg Neg Neg  Neg Neg Neg 
CD34 Neg Neg Neg  Neg Neg Neg 
CD35 Neg Neg Neg  Neg Neg Neg 
        
GROUP LL (low level) 
 
HG (high level) 
        
 
5.1. Differentiation potential 
We compared the two donor groups for capability to differentiate toward different lineages. Adipogenic 
and osteogenic potentials were very similar between the HL and LL groups (Fig. 4a and b). The 
chondrogenic potential, however, differed between the LL and HL groups. Comparing cells cultured in 
differentiation medium with its control points, there was no difference in the amount of Col2A1 in the LL 
group, but an appreciable difference was seen in the HL group (Fig. 4c). 
 
 
 
Fig. 4. Staining of low level (LL) differentiated cells (CD29 expression lower than 90%) and high level (HL) differentiated cells 
(CD29 expression exceeding 90%). (a) Oil Red O staining of the two groups when differentiated toward adipocytes compared to 
controls cultured in Dulbecco’s Modified Eagles Medium (DMEM) with 20% fetal bovine serum (FBS). The photos are from day 
21 of culture. (b) Alizarin Red staining of the two groups when differentiated toward osteoblasts, compared to controls. The photos 
are from day 21 of culture. (c) Immunohistochemical results for Col2A1 in the two cell groups. For each group the comparison is 
made between controls cultured for equivalent time in DMEM with 20% FBS and cells grown in chondrogenic differentiation 
medium (CDM). 
5.2. Molecular events during chondrogenesis 
After finding significant (p<0.05) differences in the amount of Col2A1 between the LL and HL groups, 
we analyzed gene expression during the chondrogenic process at time intervals of 2, 4, 7, 14, 21, and 28 
days, in both normoxic and hypoxic conditions. In this experiment, we compared the cells cultured in 
differentiation medium with the corresponding control cells cultured in DMEM with 20% FBS at each 
time interval. 
By analysis of chondrocyte marker genes (Sox9, Agg, and Col2A1) at 14 and 21 days of 
differentiation, we found that the LL group was not capable of differentiation toward chondrocyte-like 
cells, while the HL group did differentiate (Fig. 5). In Fig. 5, 20% FBS-HL and 20% FBS-LL represent 
the control points of the two groups and CDM-HL and CDM-LL represent the cells treated with 
chondrogenic differentiation medium (CDM) belonging to the two groups. For each gene, the value 1 was 
given to the lowest expression level to allow comparative measurement. 
 
 
 
Fig. 5. Chondrogenic-specific gene expression levels of low level (LL) differentiated cells (CD29 expression lower than 90%) and 
high level (HL) differentiated cells (CD29 expression exceeding 90%) in hypoxic and normoxic conditions. Four experimental 
treatments, controls and treated cells from the HL group (20% FBS-HL and CDM-HL, respectively) and controls and treated cells 
from the LL group are compared (20% FBS-LL and CDM-LL, respectively). Control cells were cultured in Dulbecco's Modified 
Eagles Medium (DMEM) with 20% FBS, treated cells were cultured in differentiation medium for the same duration. (a) Expression 
levels of Sox9, aggrecan (Agg), and collagen type 2A1 (Col2A1) at days 14 and 21 of culture in normoxic conditions. (b) 
Expression levels of Sox9, Agg, and Col2A1 at days 14 and 21 of culture in hypoxic conditions. *indicates p<0.05. 
At day 14 of culture in normoxic conditions (Fig. 5a), the HL group cells cultured in chondrogenic 
differentiation medium (CDM-HL) displayed significantly higher expression levels (p<0.05) of Sox9, 
Agg, and Col2A1 (81.86, 91.27, and 37.66 times, respectively). At day 21 of normoxic culture, Agg and 
Col2A1 levels of the CDM-HL samples remained significantly higher at 69.65 and 105.05 times, 
respectively (p<0.05), but the level for Sox9 gene expression of treated cells was significantly (p<0.05) 
lower than that of the control (8.37 times in treated cells compared to 34.18 times in the control cells). 
Under hypoxic conditions (Fig. 5b), at day 14 of culture the levels of Sox9 and Agg did not differ 
between the controls and treated cells. Only the level of Col2A1 was significantly higher (p<0.05) in 
CDM-HL (79.89 times). At day 21 in CDM-HL the expression levels of Sox9, Agg, and Col2A1 were, 
respectively, 70.16, 51.88, and 181.65 times higher and were statistically significant (p<0.05). 
At this point, we compared the expression of chondrocyte-specific genes in the HL group comparing 
hypoxic and normoxic conditions (Fig. 6). Sox9 gene expression levels were higher at day 21 in hypoxic 
conditions (20.53 times) followed by its expression at day 14 in normoxic conditions (9.78 times). Both 
these differences were statistically significant (p<0.05). At both days 14 and 21 of differentiation, 
expression levels of Col2A1 gene were higher in hypoxic conditions (71.26 and 162.02 times, 
respectively), but without any statistical significant difference. Regarding the Agg, the expression levels 
were higher at day 14 and at day 21 in normoxic conditions (15.62 and 11.92 times, respectively) and 
both differences were statistically significant (p<0.05).  
 
 
 
Fig. 6. Expression levels of high level (HL) differentiated cells (CD29 expression exceeding 90%) during chondrogenic 
differentiation. Expression levels of Sox9, aggrecan (Agg) and collagen type 2A1 (Col2A1) at days 14 and 21 of culture in hypoxic 
and normoxic conditions. For each gene the reference value 1 is given to the lowest expression level between cells cultured in 
differentiation medium (CDM-HL) and cells cultured in DMEM with 20% fetal bovine serum (20% FBS-HL) in hypoxic and 
normoxic conditions. *indicates p<0.05. 
We then studied the expression of other genes involved in the chondrogenesis of the cartilage growth 
plate. Gene expressions of cells grown in differentiation medium from the two donor groups were 
compared. The values for each gene were calculated for each time point; the differentiation medium cells 
were compared to their corresponding controls (Fig. 7). This study permitted us to establish, in our 
experimental conditions, the different phases of the process and to understand which genes are likely to 
be essential for chondrogenesis. 
 
 
 
Fig. 7. Expression levels of low level (LL) differentiated cells (CD29 expression lower than 90%) and high level (HL) differentiated 
cells (CD29 expression exceeding 90%) during chondrogenic differentiation. For each gene at each time of assay the value is 
obtained by comparing cells cultured in differentiation medium to the same cells cultured in DMEM with 20% fetal bovine serum 
(FBS). (a) Tenascin-C (Tnc), cadherin 2 (Cdh2) and Runx2 expression levels at days 2, 7, and 14 of culture in normoxic conditions; 
(b) Tnc, Cdh2, and Runx2 expression levels at days 2, 7, and 14 of culture in hypoxic conditions. *indicates p<0.05. 
Under normoxic conditions (Fig. 7a), chondro-progenitor condensation occurred between days 2, 4, 
and 7 when the Tnc and Cdh2 genes were upregulated in the HL group. Differences in gene levels 
between the HL and LL groups were statistically significant at days 2 and 4 for the Tnc gene (p<0.05) and 
only day 4 for the Cdh2 gene (p<0.05). Differences in Runx2 gene levels occurred between days 7 and 14 
but were not statistically significant. 
Under hypoxic conditions (Fig. 7b), the up-regulation of Tnc and Cdh2 occurred between days 2, 4, 
and 7 of culture. The increases were statistically significant (p<0.05) in both the HL and LL groups at all 
three times, but differences in Cdh2 levels were statistically significant only at day 4 (p<0.05). In hypoxic 
conditions, Runx2 gene expression was significantly upregulated in the HL group at day 2 (p<0.05), and, 
even if upregulated at days 7 and 14, its different expressions were not statistically significant. 
5.3. Stem cell markers quantification 
To determine which of the two groups represents the more immature phenotype, we compared the 
expression levels of stem cell marker genes (Sox2, Nanog, and Oct3/4) at the beginning of each 
experiment. 
For each gene, the reference value 1 was given to the lowest expression level. The LL group displayed 
a more undifferentiated state with higher expression of the Sox2, Nanog, and Oct3/4 genes (6.82, 7.49, 
and 19.28 times, respectively); however, the difference in Oct3/4 expression was the only one that was 
statistically significant (p<0.05) ( Fig. 8).  
 
 
 
Fig. 8. Stem cell marker expression levels at the start of experiments comparing high level (HL) differentiated cells (CD29 
expression exceeding 90%) and low level (LL) differentiated cells (CD29 expression lower than 90%). For each gene the reference 
value 1 is given to the lowest expression level. *indicates p<0.05. 
6. Discussion 
The interest in MSCs and their possible application in cell therapy have resulted in a better understanding 
of the basic biology of these cells. 
Bone marrow represents the most commonly used tissue source for the isolation of MSCs (Pittenger et 
al., 1999), but due to the low number of cells that can be isolated, culture expansion is necessary to obtain 
adequate cell numbers for clinical purposes and for the analysis of molecular mechanisms. 
In this study, we addressed the question of use of surface antigen selection of MSC populations. Our 
work focused on two aims: to identify a population with higher chondrogenic potential for possible 
application in cell therapy to treat cartilage defects and to elucidate the mechanism underlying 
chondrogenic differentiation. We therefore analyzed two different populations: one obtained through the 
positive magnetic selection of cells having the CD105 surface antigen (CD105+) and the second from 
unselected BM-MSCs (total-BM). 
CD105 (human endoglin) is a homodimeric integral membrane glycoprotein highly expressed in 
MSCs. It belongs to the transforming growth factor-β (TGF-β) receptor system (Cheifetz et al., 1992) and 
binds TGF-β1 and TGF-β3 to form a heteromeric complex with TGF-β type I and/or TGF-β type II 
receptors (Bellon et al., 1993). CD105 also interacts with bone morphogenetic protein-7 (BMP-7), 
associating with activin type II receptors, and with BMP-2, associating with ligand binding type I 
receptors (Barbara et al., 1999). Looking for the chondrogenesis, where members of the transforming 
growth factor family represent important signals in the development of cartilage tissue, we answered the 
question if CD105 presence could be helpful in chondrogenic differentiation. 
To investigate the properties of our two MSC populations, we compared the characteristics of our 
culture-expanded cells for phenotypic profiles, multi-lineage differentiation potential and expression of 
the stem cell marker genes, Nanog, Oct3/4, and Sox2. 
A number of previous studies using CD105+-enriched MSC populations have been reported. Some of 
these assessed the differentiation capacity and the phenotypic characteristics of the selected cells, 
providing some indications of their chondrogenic capacity (Arufe et al., 2009 and Majumdar et al., 2000) 
and osteogenic potential (Aslan et al., 2006). Other studies compared different populations (Kastrinaki et 
al., 2008 and Jarocha et al., 2008) and demonstrated that the culture expansion necessary to obtain a 
sufficient number of cells leads to the development of similar characteristics in the different populations. 
After three to five passages, our cell populations displayed similar phenotypes, both related to that of 
MSCs. Both populations were positive for CD105, CD90, CD44, CD29, CD73, and CD44 and negative 
for CD34 and CD45. In addition, both populations displayed similar differentiation potentials for 
adipogenic, osteogenic, and chondrogenic lineages. Finally, the stem cell marker gene expressions were 
not significantly different. 
The results during the course of the experiments led us to analyze the data for individual donors. The 
phenotypic profiles of the donors suggested a division into two groups based on the amount of CD29 (β1-
integrin) surface antigen. We designated the donors with the higher expression level of CD29 
(CD29>90%) as the HL group and the donors with the lower expression level (CD29<90%) as the LL 
group. Dividing the donors in this way permitted also the separation of the donors according to 
chondrogenic capability. 
Although cells from the HL and LL groups displayed similar differentiation potential for adipogenic 
and osteogenic lineages, their chondrogenic potential was markedly different. This difference could be 
seen both in the immunohistochemistry results for the amount of Col2A1 and in the qPCR results for the 
expression of chondrocyte-specific genes. The LL group did not have any significant differences between 
treated cells and control cells. However, the HL group treated cells had more capacity for chondrogenic 
differentiation capacity than their control cells. The HL group also had a higher expression of CD29; 
these results point to a strict relationship between the chondrogenic capacity of cells and the level of 
CD29 expression. 
CD29 is an integrin β-1 protein. Integrins are heterodimeric membrane receptors made up of alpha 
and beta subunits and are involved in cell–cell or cell–matrix interactions (Hynes, 1987). In general, these 
interactions are important for regulation of cell migration (Hemler, 1990), cartilage development (Woods 
et al., 2007), and cell survival (Cao et al., 1999). Regarding cartilage development and function, it has 
been described that administration of anti-β1 antibodies to cultures of mouse limb bud mesenchymal cells 
inhibits the formation of cartilagineous nodules (Shakibaei, 1998), suggesting a role of CD29 during both 
mesenchymal condensation and chondrocyte differentiation. In addition, deletion of β1 integrin in the 
limb bud results in multiple abnormalities of knee joints, playing a pivotal role in joint development and 
in its structural organization (Raducanu et al., 2009). Finally, mutant mice carrying a cartilage-specific 
deletion of the β1 integrin gene develop a chondrodysplasia of various severities (Aszodi et al., 2003). 
As reported in a recent study (Choi et al., 2009), we suggest the importance not only of the presence 
or absence of a receptor and its ligand but also of the density and affinity of interactions between those 
two entities. In addition, it is important to keep in mind the possibility that CD29 may heterodimerize 
with various alpha subunits, giving rise to different types of integrins. 
We analyzed the chondrogenesis process in the HL group. Through the comparison of days 14 and 21 
of hypoxic and normoxic conditions, like in other papers (Koay and Athanasiou, 2008), we observed that 
gene expression levels of Col2a1 were higher in both times of analysis when the differentiations were 
carried out in a hypoxic environment. The gene levels of Sox9 were higher at day 21 in hypoxic 
condition, while Agg gene levels were higher at days 14 and 21 of normoxic conditions. Then, looking 
for the mechanism underlying chondrogenic differentiation of HL group, in agreement with earlier 
studies, we found a process similar to the one seen in growth plate cartilage. This process is initiated by 
the recruitment and condensation of mesenchymal cells, which depend on signals initiated by cell–cell 
and cell–matrix interactions (Cohn and Tickle, 1996). This cellular condensation is associated with the 
appearance of cell adhesion molecules, such as neural cadherin (Cdh2) (DeLise and Tuan, 2002) and 
tenascin-C (Tnc) (Mackie et al., 1987), that disappear in differentiating chondrocytes. In every 
condensation, one transcription factor is always expressed. This is runt-domain transcription factor 
Runx2, which is also known as core binding factor (Cbfa1) (Ducy et al., 1997). In this chondro-progenitor 
condensation step, we found an initial up-regulation of Tnc and Cdh2 at culture days 4 and 7, coinciding 
with the strengthened cell–cell interactions that follow the condensation stage (Chimal-Monroy and Díaz 
de León, 1999). The expression levels of Runx2, however, were not statistically significant at any culture 
time. As chondrogenesis differentiation continues, one of the earliest markers expressed is nuclear 
transcription factor Sox9 (Bi et al., 1999), required for differentiation of the chondro-progenitor cells to 
mature chondrocytes as well as for deposition of the cartilage matrix containing chondrocyte-specific 
genes, such as collagens II, IX, XI, and aggrecan (Lefebvre et al., 1997). In our experimental conditions, 
this step occurred between days 14 and 21, coinciding with the up-regulation of Sox9, Col2A1, and Agg 
genes. The last step in the differentiation process is hypertrophy of the chondrocytes, leading to cartilage 
matrix ossification and vascular invasion (Ortega et al., 2004). The hypertrophic phenotype is 
characterized by an up-regulation of Runx2 in early hypertrophy, and of Col10 and MMP13 in the later 
hypertrophic stages. We indeed found an up-regulation of Col10 and MMP13 at day 28 of differentiation, 
confirming the hypertrophic state. None of these gene expression variations were seen in the gene 
expression analysis of the LL group samples. 
The last part of our study was the gene expression analysis for the stem cell marker genes, Sox2, 
Nanog, and Oct3/4. At the beginning of the experiments, higher expression levels of these markers were 
found in the LL group, the one with the lower chondrogenic potential. As seen in a previous study, lower 
gene expressions characteristic of stem cells were associated with a robust and efficient differentiation 
into chondrocyte-like cells (Lian et al., 2007). It is probable that the higher levels of stem cell gene 
markers in the population with the poorest differentiation would relate to different capabilities of the 
various isoforms of these genes (Lee et al., 2006). It is necessary to delve deeply into gene expression 
studies when the object is the prediction of stem cell activity. 
In conclusion, in this work we highlight the importance of the BM-MSC donor. It would be very 
useful to identify the differences in phenotypes of donor cells that influence increased capability for 
adipo-, osteo- or chondrogenic differentiation. In our experimental conditions, we found a correlation 
between CD29 expression and the chondrogenic capacity of cells. This suggests the importance of a high 
level of expression of the CD29 antigen when selecting BM-MSCs with a higher chondrogenic potential. 
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